(DOWNLOAD) "Antibodies: another idea for COVID-19" by Jumper General # Book PDF Kindle ePub Free
eBook details
- Title: Antibodies: another idea for COVID-19
- Author : Jumper General
- Release Date : January 27, 2020
- Genre: Medical,Books,Professional & Technical,
- Pages : * pages
- Size : 2858 KB
Description
All English content is listed below. There is Chinese content in the book. If you think this book is valuable, please buy this book to support me.
Antibodies: another idea for COVID-19
COVID-19 is somewhere between flu and SARS. The effects on young and old people are significantly different, with mortality rates approaching SARS in the elderly and close to severe influenza in the young.
In addition to direct medication, the medical community has focused on vaccine development. However, the severe transmission rate of COVID-19 continue to increase the number of deaths. It takes a year at the earliest to develop a vaccine, and it cannot solve the serious social, political and economic problems currently facing.
In addition to drugs and vaccines, there is actually an "antibody" that can be used very well. Antibodies are not valued, most likely because of insufficient incentives. Neither scientists nor pharmaceutical companies are profitable. Because antibodies are produced spontaneously by patients, they have nothing to do with any scientist or pharmaceutical company. However, the government as a society's management role, it should abandon economic interference and consider all effective means.
Antibodies are the products of the body's own immune system against pathogens, and the role of vaccines is to induce the body to produce antibodies. However, antibodies are not only produced by vaccines. The production of antibodies by vaccines is actually the second way to produce antibodies. The first method of production is that the disease directly causes the patient to produce antibodies.
If the antibodies are not effective, the vaccine is less likely to be effective. This is the most important assumption of this article.
Although the current epidemic situation in countries around the world varies from a few thousandths to a few percent, the chance of survival is always more than 90 percent. And all currently surviving patients are self-healing patients whose autoimmune system defeats the SARS-CoV-2 virus. (Note: There are probably dozens of cases of plasma treatment in China.) COVID-19 is a self-limiting disease, and self-healing is almost the only path to cure at present, by the means to produce antibodies against SARS-CoV-2. All medical methods help to produce this antibody in the immune system. If antibody plasma therapy is available, it will add a true "therapeutic" approach, rather than all the self-healing properties available today.
Therefore, my suggestion is to increase the focus on antibodies and re-examine the formulation of various social, political and economic policies during the epidemic.
in particular:
1, After more than 90% of the patients healed, most of the self-healing patients had antibodies against the SARS-CoV-2 virus. This antibody plasma should be collected for treatment of critically ill patients to reduce mortality. Increase the research intensity of antibody plasma therapy. Actively using antibodies in the plasma of self-healing patients to counteract the peak of the epidemic, eventually steadily transitioning to successful vaccine development. Judging from the current limited plasma treatment experience in China, there are no cases of deterioration, and the rate of improvement and cure is very high.
2, The political measures suspended by society as a whole are not optimal solutions. In this epidemic, it is too costly to adopt social prevention and control measures to cope with the SARS epidemic. Such measures should not be implemented in an area unless there is a risk of overloading the medical system in that area. It is of course necessary to track and control the source of infection, and the control measures should also be adapted to the characteristics of the epidemic, and gradually decrease according to age. Young people, under 35, should not be completely banned from studying, working, and living. The injunction should target people aged 60 or over. Middle-aged people should take good protective measures and try to work from home. The problem of contact and dissemination of young people with the elderly and middle-aged people is a realistic problem that deserves attention. The suspension of the whole society has hindered the possibility of young people becoming an antibody bank, when young people are the group that is least afraid of the epidemic. In many countries, the proportion of young people living alone is high, and excessive restrictions on their freedom are not always necessary.
3, Resources are tilted towards the medical system, with the primary goal of improving healing efficiency. The goal is to accelerate a positive flow and facilitate the increase of antibody plasma storage capacity for antibody plasma therapy. According to the current status of the age group, the cure rate can hardly be changed by technical means. Only after the healing efficiency is improved can there be enough resources to stabilize the healing rate. This is also the current practice in countries with severe outbreaks. The cure rate should not be pursued, but the cure efficiency should be pursued, especially in the early stages. The cure rate is a false concept when the outbreak is happening, because it is impossible to know the total number of patients. Healing efficiency is the concept that doctors can actually operate.
4, Antibody plasma therapy should be used primarily for severe treatment. It should be avoided as much as possible for mild patients with the possibility of self-healing, because it is not guaranteed to be free from subsequent infection. Patients cured with antibody plasma should self-isolate to the end of the epidemic. It is worth noting that patients cured with antibody plasma cannot donate plasma because they do not produce antibodies spontaneously in the body. Those imported antibodies will disappear from the body within half a month to a month. Non-self-healing patients' plasma is useless. Antibody testing should be universal to facilitate plasma collection.
5, Because the antibodies needed for plasma therapy come from patients, it is recommended that each volunteer who donates antibody plasma be awarded between $ 1,000 and $ 3,000.
6, For the current epidemic alone, antibodies provided by self-healing patients should be sufficient to cope with any peak of the epidemic. It only takes one treatment cycle to implement the program. The epidemic has been developing for several months and there are sufficient antibody plasma banks available.
7, What I don't understand is that, antibodies as protein, mass production should be much less difficult than vaccines. If it can be mass-produced, the price of the antibody required to treat each patient is reasonable at a few hundred dollars. However, antibodies are equivalent to disposable drugs and cannot fight the virus for a long time, so vaccines still have value.
The epidemic will eventually pass. With the powerful intervention of various measures, I hope that the time will be shorter and the cost will be less.
[20200505]
I saw good news today. On May 4, the "Single Cell Neutralizing Antibody" developed by the Israel Institute of Biology can neutralize the SARS-CoV-2 virus in patients with COVID-19. This unique single cell antibody formulation has been patented and is seeking mass production by international manufacturers. I am in a good mood and the COVID-19 pandemic is over soon.
[/20200505]
[20200506]
Antibody medicines have a logical combination of technical levers. It can provide backup safety guarantee for live attenuated vaccine or inactivated vaccine, and increase the application speed of these two types of vaccines.
For example, after the first-stage screening, a larger-scale second-stage vaccination is performed. Or, after the second screening, insert a challenging 2.5-stage large-scale vaccination. Of course, this is based on the premise of effective safety screening of candidate vaccines.
The adverse consequences of live attenuated vaccines or inactivated vaccines are within the capabilities of antibody medicines, so logically it is a good solution.
[/20200506]
 "Antibodies: another idea for COVID-19" by Jumper General # Book PDF Kindle ePub Free){kind=link}